文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

继发性二尖瓣反流:病理生理学、比例性与预后

Secondary mitral regurgitation: pathophysiology, proportionality and prognosis.
PubMed 文献 · Heart · 2020-02-13

继发性二尖瓣反流(SMR)由左房室功能障碍和多因素不良重构引起,是最常见且治疗不足的二尖瓣反流类型,预后极差。SMR是否为心肌病严重程度的旁观者长期存在争议,研究提示SMR是中间型心衰表型患者预后的独立驱动因素,而非晚期心衰患者。2018年MITRA-FR与COAPT两项随机对照试验结果对比鲜明又互补,COAPT显示经导管二尖瓣修复带来显著预后获益,主要归因于选择了二尖瓣反流程度相对于心衰表型不成比例严重的患者。

要点

  • SMR是中间型心衰表型患者预后的独立驱动因素,而非晚期心衰患者。
  • COAPT试验显示经导管二尖瓣修复在适当选择的患者中带来显著预后获益。
  • 量化SMR程度与左心室容积的关系可能有助于预测经导管介入治疗的成功。

核心结论

  • SMR是中间型心衰表型患者预后的独立驱动因素,而非晚期心衰患者。
  • COAPT试验显示经导管二尖瓣修复带来显著预后获益,主要归因于选择了二尖瓣反流程度相对于心衰表型不成比例严重的患者。
  • 量化SMR程度与左心室容积的关系可能有助于预测经导管介入治疗的成功。

研究设计与样本

  • 本文为综述,总结了SMR的病理生理学、比例性与预后相关证据及两项随机对照试验结果。

主要发现

  • SMR是最常见且治疗不足的二尖瓣反流类型,与极差预后相关。
  • SMR是否为心肌病严重程度的旁观者长期存在争议。
  • 研究提示SMR是中间型心衰表型患者预后的独立驱动因素,而非晚期心衰患者。
  • 2018年MITRA-FR与COAPT两项随机对照试验报告了对比鲜明又互补的结果,COAPT显示显著预后获益。

关键数值与推荐

  • 目前对于定义严重SMR的定量阈值尚无普遍共识,超声心动图定量存在挑战。
  • COAPT试验中经导管二尖瓣修复带来显著预后获益,主要归因于选择了二尖瓣反流程度相对于心衰表型不成比例严重的患者。

临床怎么用

  • 在中间型心衰表型患者中应重视SMR的预后意义。
  • 经导管介入治疗前应评估SMR程度与左心室容积的关系,以识别可能获益的患者。
  • 维持以心脏团队为指导的整体评估方法。

局限性

  • 目前对定义严重SMR的定量阈值尚无普遍共识,超声心动图定量存在挑战。
  • 未来需识别并验证可用于预测经导管介入治疗成功的参数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary mitral regurgitation (SMR) occurs as a result of multifactorial left atrioventricular dysfunction and maleficent remodelling. It is the most common and undertreated form of mitral regurgitation (MR) and is associated with a very poor prognosis. Whether SMR is a bystander reflecting the severity of the cardiomyopathy disease process has long been the subject of debate. Studies suggest that SMR is an independent driver of prognosis in patients with an intermediate heart failure (HF) phenotype and not those with advanced HF. There is also no universal agreement regarding the quantitative thresholds defining severe SMR and indeed there are challenges with echocardiographic quantification. Until recently, no surgical or transcatheter intervention for SMR had demonstrated prognostic benefit, in contrast with HF medical therapy and cardiac resynchronisation therapy. In 2018, the first two randomised controlled trials (RCTs) of edge-to-edge transcatheter mitral valve repair versus guideline-directed medical therapy in HF (Percutaneous Repair with the MitraClip Device for Severe (MITRA-FR), Transcather mitral valve repair in patients with heart failure (COAPT)) reported contrasting yet complimentary results. Unlike in MITRA-FR, COAPT demonstrated significant prognostic benefit, largely attributed to the selection of patients with disproportionately severe MR relative to their HF phenotype. Consequently, quantifying the degree of SMR in relation to left ventricular volume may be a useful discriminator in predicting the success of transcatheter intervention. The challenge going forward is the identification and validation of such parameters while in parallel maintaining a heart-team guided holistic approach.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Chehab O, Roberts-Thomson R, Ng Yin Ling C, et al. Secondary mitral regurgitation: pathophysiology, proportionality and prognosis. Heart. 2020. PMID: 32054671. doi:10.1136/heartjnl-2019-316238

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。